Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) shot up 2.7% during trading on Tuesday . The stock traded as high as $4.32 and last traded at $4.26, with a volume of 70,959 shares changing hands. The stock had previously closed at $4.15.

Several research firms have recently commented on VBLT. Zacks Investment Research raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Thursday, July 14th. HC Wainwright assumed coverage on shares of Vascular Biogenics in a report on Tuesday, June 28th. They issued a “buy” rating and a $11.00 target price for the company. Roth Capital reiterated a “buy” rating and issued a $22.00 target price on shares of Vascular Biogenics in a report on Thursday, June 9th. Chardan Capital reiterated a “buy” rating on shares of Vascular Biogenics in a report on Tuesday, June 7th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and issued a $14.00 target price on shares of Vascular Biogenics in a report on Tuesday, June 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $16.50.

The firm’s 50 day moving average is $4.12 and its 200-day moving average is $3.66. The company’s market capitalization is $96.20 million.

Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). Analysts expect that Vascular Biogenics Ltd. will post ($0.82) earnings per share for the current fiscal year.

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.